References
- Savage LJ, Layton AM. Treating acne vulgaris: systemic, local and combination therapy. Expert Rev Clin Pharmacol. 2010;3:563–580.
- Cunliffe WJ, van de Kerkhof PC, Caputo R, Cavicchini S, Cooper A, Fyrand OL, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology. 1997;194:351–357.
- Cooper AJ. Isotretinoin: which dosage? Australas J Dermatol. 1997;38:183–184.
- Cunliffe WJ, Layton A, Knaggs HE, Stubbings J, Taylor JP. Isotretinoin and acne: A long-term study. In Saurad JH, editor. Retinoids: 10 Years On. S Karger, Basel: 1991. p 274–280.
- Lehucher-Ceyrac D, Weber-Buisset MJ. Isotretinoin and acne in practice: A prospective analysis of 188 cases over 9 years. Dermatology. 1993;129:292–296.
- Ng PP, Goh CL. Treatment outcome of acne vulgaris with oral isotretinoin in 89 patients. Int J Dermatol. 1999;38:213–216.
- Ostlere LS, Harris D, Morse-Fisher N, Wright S. Effect of systemic administration of isotretinoin on blood lipids and fatty acids in acne patients. Int J Dermatol. 1996;35:216–218.
- Goodfield MJD, Cox NH, Bowser A, McMillan JC, Millard LG, Simpson NB, et al. Advice on the safe introduction and continued use of isotretinoin in acne in the U.K. 2010. Br J Dermatol. 2010;162:1172–1179.
- Sundström A, Alfredsson L, Sjölin-Forsberg G, Gerden B, Bergman U, Jokinen J. Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ. 2010;341:c5812.
- Rademaker M. Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin. Australas J Dermatol. 2010;51:248–253.
- Sardana K, Garg VK. Efficacy of low-dose isotretinoin in acne vulgaris. Indian J Dermatol Venereol Leprol. 2010;76:7–13.
- Borghi A, Mantovani L, Minghetti S, Giari S, Virgili A, Bettoli V. Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission. J Eur Acad Dermatol Venereol. 2011;25:1094–1098.
- Lehman HP, Robinson KA, Andrews JS, Holloway V, Goodman SN. Acne therapy: A methodologic review. J Am Acad Dermatol. 2002;47:231–240.
- Allen BS, Smith G Jr. Various parameters for grading acne vulgaris. Arch Dermatol. 1982;118:23–25.
- Tang MBY, Tan EST, Tian EAL, Loo SC, Chua SH. Electronic e-isotretinoin prescription chart: Improving patients' adherence to isotretinoin prescription guidelines. Australas J Dermatol. 2009;50:107–112.
- Al-Khawajah MM. Isotretinoin for acne vulgaris. Int J Dermatol. 1996;35:212–215.
- Hogan DL, Strand LM, Lane PR. Isotretinoin therapy for acne: a population-based study. Can Med Assoc J. 1988;138:47–50.
- Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol. 2006;54:644–646.
- McLane J. Analysis of common side effects of isotretinoin. J Am Acad Dermatol. 2001;45:S188–S194.
- Walker BR, MacKie RM. Serum lipid elevation during isotretinoin therapy for acne in the West of Scotland. Br J Dermatol. 1990;122:531–537.
- Previsani N, Lavanchy D, Hepatitis B. WHO/CDS/CSR/LYO/2002.2. Available from: http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf.
- Ong SC, Lim SG, Li SC. How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore. J Viral Hepat. 2009;16:53–63.